MAIA Biotechnology (MAIA) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, with lead asset ateganosine (THIO) targeting telomere biology and immunogenicity.

• Initial focus is on Non-Small Cell Lung Cancer (NSCLC), with additional trials planned for hepatocellular carcinoma, colorectal cancer, and small cell lung cancer.

• Operations based in Chicago, with subsidiaries in Australia and Romania to support clinical and preclinical activities.

• Strategic collaborations with Regeneron, BeOne Medicines, and Roche for clinical supply and combination studies.

Financial performance and metrics

• Incorporated in 2018; has incurred losses since inception and expects increasing losses as clinical development progresses.

• Requires additional capital to fund operations and clinical trials; future financing needs are significant.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general working capital and potentially for acquisitions of complementary businesses or technologies.

• Management retains broad discretion over allocation of proceeds, with no specific commitments as of the filing date.